-
Story
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next -
Press Release
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
-
Press Release
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
-
Press Release
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
-
Story
The future of medicine is here -
Press Release
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
-
Story
Take a visual tour of medicines that target RNA -
Press Release
Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition
-
Story
Need for new heart disease medicines drives wave of potential therapies -
Story
Minion challenges assumptions about the genome -
Story
Building brain organoids to shed light on disease -
Story
Collaborating to unlock secrets of the microbiome